Many patients may have to switch obesity drugs now that CVS Caremark opted to stop offering tirzepatide (Zepbound) in favor ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

As part of the move, Caremark will also drop Eli Lilly's weight loss drug Zepbound from ... "In our view, the Novo/CVS deal does not represent the beginning of an obesity pricing war between ...

NEW YORK — CVS ... obesity medications known as GLP-1 receptor agonists that have soared in popularity due to the amount of weight people lose while taking the injections. Coverage of these ...

He said the deal would reduce the price that Caremark’s employer clients paid for obesity drugs by 10% to 15% compared with the previous year. Advertising “CVS Caremark was able to do what ...